- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Sun Pharma Advanced Research Company Limited reported a challenging quarter for the period ended September 30, 2024. Revenue from operations reached ₹1,286 crore, a decline from ₹1,681 crore in the previous quarter and ₹2,118 crore in the same quarter last year. Other income also fell significantly to ₹4 crore compared to ₹156 crore sequentially and ₹849 crore year-on-year, leading to total income of ₹1,290 crore.
Total expenses for the quarter came in at ₹1,290 crore, with key costs including employee benefits and clinical trial expenses. The company recorded a loss before tax of ₹(10,769) crore, worsening from a loss of ₹(9,684) crore in the previous quarter and ₹(8,642) crore year-over-year. The net loss for the period was ₹(10,769) crore, resulting in a basic and diluted loss per share of ₹(3.32).
For the half-year, total income fell to ₹3,127 crore, driven by ongoing operational difficulties. The company continues to face cash losses and highlights unutilized credit limits that underpin its 'Going Concern' status. The outlook appears subdued; investors should monitor the company's strategic moves closely to see if operational improvements can be realized.
All announcements from Sun Pharma Advanced Research Company Limited